The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).
 
Takayuki Nakayama
No Relationships to Disclose
 
Makiko Yamashita
No Relationships to Disclose
 
Toshihiro Suzuki
No Relationships to Disclose
 
Manami Shimomura
No Relationships to Disclose
 
Tetsuya Nakatsura
No Relationships to Disclose
 
Kazunori Aoki
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Naoya Yamazaki
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Research Funding - MSD; Novartis; Ono Pharmaceutical; Takara Bio
 
Taiki Isei
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Kaken Pharmaceutical; Kyowa Hakko Kirin; Maruho; Merck Sharp & Dome; Mochida Pharmaceutical Co. Ltd.; Novartis; Ono Pharmaceutical; Pfizer; Pola Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dome; Novartis; Ono Pharmaceutical
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Sharp & Dome; Novartis; Ono Pharmaceutical; Takara Bio
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Kaken Pharmaceutical; Kyowa Hakko Kirin; Maruho; Merck Sharp & Dome; Novartis; Ono Pharmaceutical
 
Hisashi Uhara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Maruho; MSD; Novartis; Ono Pharmaceutical; Porafarma
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Janssen; Kyowa Hakko Kirin; Mitsubishi Tanabe Pharma; MSD; Novartis; Ono Pharmaceutical
Research Funding - Abbvie; Daiichi Sankyo; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Maruho; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Pola Pharma; Taiho Pharmaceutical; Torii Pharmaceutical; Tsumura & Co.
 
Yoshio Kiyohara
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Takara Bio; Torax Medical
Research Funding - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Ono Pharmaceutical; Takara Bio
Travel, Accommodations, Expenses - Ono Pharmaceutical
 
Hiroshi Uchi
No Relationships to Disclose
 
Hiroshi Saruta
Speakers' Bureau - Kyowa Hakko Kirin; Minophagen Pharmaceuticals; Ono Pharmaceutical
Research Funding - Minophagen Pharmaceuticals (Inst); MSD (Inst); Takara Bio (Inst)
 
Takashi Inozume
No Relationships to Disclose
 
Maki Tanaka
Employment - Merck (I); Takara Bio
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Meiji Seika Kaisha; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Sumitomo Group; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio